Commercial Uses of Different Lipid-Based Nanovesicles in Current Scenario

Abstract

Nanoparticles have emerged as a promising alternative to conventional methods in various fields, including the pharmaceutical industry. They have been used to preserve drugs with potential therapeutic benefits, find new uses for old medicines, and deliver biopharmaceuticals. Despite the advancements in drug delivery systems, conventional methods often face significant challenges, including poor solubility, limited bioavailability, and systemic side effects. These limitations hinder the effective delivery of both hydrophilic and lipophilic therapeutic agents, resulting in suboptimal treatment outcomes. Lipid-based nanovesicles (L-NVs) have emerged as a promising solution to these challenges, offering enhanced stability, targeted delivery, and improved therapeutic efficacy. However, the transition of L-NVs from laboratory research to commercial application is fraught with regulatory hurdles, manufacturing complexities, and the need for rigorous safety and efficacy assessments. This chapter introduces the extensive range of L-NVs currently available, focusing on the latest generation of non-liposomal L-NVs, and highlighting their similarities and differences.